Navigation Links
Triple Negative Cancer Research Could Benefit All Breast Cancer Patients
Date:1/31/2011

FREDERICKSBURG, Va., Jan. 31, 2011 /PRNewswire/ -- Research to develop more effective treatments for triple negative breast cancer -- a difficult disease to cure -- could someday benefit all breast cancer patients, reports Dr. Frederick C. Tucker, Jr. of Fredericksburg Oncology.

"Understanding how triple negative cancers spread in the absence of normal growth factors may give us insight into how other types of breast cancer grow and spread even after treatment," Dr. Tucker explains.

Recent research has shown that a new class of drugs, PARP inhibitors, can be combined with chemotherapy to kill more triple negative breast cancer cells. Research also indicates that platinum compounds, a type of chemotherapy not typically prescribed for breast cancer, may be useful in treating triple negative disease.

Currently, two trials offered at Fredericksburg Oncology focus on triple negative disease.

  • CALGB 40603:  Pre-operative (neoadjuvant) chemotherapy for triple-negative breast cancer involving platinum chemotherapy (carboplatin) and bevacizumab.
  • NCCTG N0937:  Platinum chemotherapy (Cisplatin) and brostacillin for metastatic triple-negative breast cancer

An estimated 15 percent of breast cancers are triple negative, meaning they do not have receptors for estrogen, progesterone, and for the growth factor receptor HER2.  Breast cancer treatments such as Tamoxifen, Arimidex, Femara, and Herceptin which target these molecules are therefore not helpful against triple negative disease. Standard chemotherapies can be used in triple negative breast cancer, but they may not be as effective as they are for more common breast cancers.

For more information about clinical trials offered through Fredericksburg Oncology, visit http://fredericksburgoncology.com/wp/about-clinical-trials/.  Email regarding clinical trials can be sent to info@fred-onc.com or call (540) 368-0500.

About Fredericksburg Oncology

Fredericksburg Oncology specializes in providing high quality treatment for the medical and emotional needs of cancer patients. Since 2006, the practice also has been committed to providing clinical research. It is located at 111 Park Hill Drive, Suite B, Fredericksburg, VA 22401 near Mary Washington Hospital. For more information call (540) 368-0500 or visit www.fredericksburgoncology.com.

Dr. Frederick C. Tucker, Jr. is board certified in oncology, internal medicine, and psychiatry. He also is a writer and speaker on cancer-related topics. To read Dr. Tucker's recent commentary, visit http://fredericksburgoncology.com/wp/topics/news/ or connect with him on Facebook.


'/>"/>
SOURCE Fredericksburg Oncology
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sanofi-aventis Reports Top-line Results from Phase III Study with Iniparib (BSI-201) in Metastatic Triple-Negative Breast Cancer
2. Positive Phase II Results with Iniparib (BSI-201) in Women with Metastatic Triple Negative Breast Cancer Published in The New England Journal of Medicine
3. Novartis Gains FDA Approval for Amturnide™, a Triple-Combination Pill to Treat High Blood Pressure in Patients Uncontrolled on Two Medications
4. By 2019, the Acute Gout Drug Market Will Triple in Size While the Chronic Gout Drug Market Will Reach $1.83 Billion
5. The Hepatitis C Virus Drug Market Will More Than Triple by 2014 but, Thereafter, the Market Will Decline Substantially Through 2019 Due to Decreasing Disease Prevalence and the High Efficacy of New Treatments
6. The Hepatitis C Virus Drug Market Will Nearly Triple by 2014 but, Thereafter, the Market Will Decline Substantially Through 2019 Due to Decreasing Disease Prevalence and the High Efficacy of New Treatments
7. Reportlinker Adds Triple Analysis: Apoptosis, Angiogenesis and Protein Kinase Inhibitors
8. EndoChoice® Triples Facility Space to Address Growing Customer Base
9. New Data Shows Investigational Triple Antihypertensive Combination Therapy Significantly Lowers Blood Pressure in Hard-to-Treat Patients with Hypertension and Diabetes
10. In Vitro Study of Adamas Pharmaceuticals Triple Combination Antiviral Drug Therapy Shows Activity Against Drug-Resistant Influenza Viruses
11. Adamas Pharmaceuticals Signs CRADA With U.S. Navy to Conduct Preclinical Studies of Triple-Combination Antiviral Drug Therapy for Influenza A, Including the Novel H1N1 Pandemic Strain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Calif. , Feb. 11, 2016 ... the use of the iFuse Implant System, a ... for certain disorders of the sacroiliac (SI) joint, ... the cost benefits of MIS SI joint fusion ... due to degenerative sacroiliitis or SI joint disruption.  ...
(Date:2/11/2016)...  Ionis Pharmaceuticals, Inc. (NASDAQ: IONS ) announced today ... 25 at 11:30 a.m. Eastern Time to discuss its 2015 ... www.ionispharma.com . A webcast replay will be available ... www.ionispharma.com . A webcast replay will be available for ... Interested parties may listen to the call by dialing 877-443-5662 ...
(Date:2/11/2016)... Feb. 11, 2016  Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD ... the development of a once-daily, oral therapy for the ... Medical Officer, Dr. Maya Halpern , has notified the ... Medical Officer and from its Board of Directors effective ... retirement age. Allen Baharaff . Mr. Baharaff ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... ... As part of their 2015 end of year funding strategy, Colleen’s ... gifted $10,000 to University of Chicago to support ovarian cancer research being conducted by ... honored to support a promising young investigator from Dr. Lengyel’s lab at the University ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... the World Molecular Imaging Congress (WMIC), will be held in New York City, ... is “Imaging Biology…Improving Therapy.” The congress will highlight and emphasize how imaging reveals ...
(Date:2/10/2016)... ... 2016 , ... Early this week, Team Iconic at J. Walter Thompson and ... the first global confectionery brand sourced from 100% sustainable cocoa. , The Nestlé Cocoa ... product, through activities that focus on better farming, better lives and better cocoa. In ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... offering education, research and medical media, has launched Contagion® , a ... diseases. , As the all-inclusive resource for infectious disease information, Contagion features ...
(Date:2/10/2016)... ... February 10, 2016 , ... MetLoop CEO ... new 2.0 version at the International Roofing Expo in Orlando, Florida on February ... world's most advanced weather technology in the hands of consumers, roofing contractors, manufacturers ...
Breaking Medicine News(10 mins):